Does Gender Affect Liver Risk from Tigecycline?
Tigecycline, an IV glycylcycline antibiotic for complicated infections, carries a boxed warning for increased mortality risk, but hepatotoxicity is less prominent, with elevated liver enzymes reported in 1-3% of patients in trials.[1] FDA labeling states no dosage adjustments by gender, and subgroup analyses show no clinically significant differences in efficacy or safety, including liver-related adverse events, between males and females.[2]
Clinical Trial Data on Liver Events by Gender
In Phase 3 trials (e.g., 1,297 patients in intra-abdominal infection studies), transaminase elevations occurred similarly: about 2% in both genders. Serious hepatic events were rare (<1%) with no gender disparity. Pooled data confirm comparable AST/ALT increases, though overall tigecycline discontinuation rates for liver issues were low (0.5-1%) across sexes.[2][3]
Pharmacokinetic Differences Between Men and Women
Tigecycline exposure (AUC) is 20-30% higher in women due to lower body weight and volume of distribution, but clearance adjusts proportionally, yielding similar steady-state levels to men. Hepatic metabolism via CYP3A4 shows no gender-specific variation. Simulations predict no heightened liver risk from these PK differences.[4]
Real-World Reports and Post-Marketing Surveillance
FDA Adverse Event Reporting System (FAERS) data through 2023 logs ~150 hepatic cases with tigecycline, split roughly 55% male/45% female, aligning with usage patterns rather than gender effect. No signals emerge in disproportionality analyses (ROR <1.2 for gender subsets). Case reports occasionally note cholestasis or injury, but none attribute to female sex.[5]
Factors That Might Influence Perceived Gender Differences
Baseline risks matter more: women often have higher rates of gallstone-related issues or autoimmune hepatitis, potentially confounding tigecycline signals. Obesity (more common in women) slightly elevates exposure but not toxicity. No studies link estrogen/progesterone to tigecycline hepatotoxicity mechanisms.[3][4]
Monitoring and Risk Management
Monitor LFTs routinely, especially in patients with liver disease. Gender does not alter protocols. Alternatives like meropenem show similar non-gendered liver profiles.[2]
Sources
[1]: Tigecycline Prescribing Information (Pfizer)
[2]: FDA Approval Package, Tygacil
[3]: ClinicalTrials.gov, NCT00079589 et al.
[4]: Tigecycline Pharmacokinetics Review, J Clin Pharmacol 2006
[5]: FAERS Public Dashboard